全程化药学服务对晚期肺癌免疫治疗患者的影响  

Effect of Whole-process Pharmaceutical Care on Patients with Advanced Lung Cancer Immunotherapy

作　　者：卫晓晓[1] 邓淑芳 李玉珍[1] 刘青 Wei Xiaoxiao;Deng Shufang;Li Yuzhen;Liu Qing(Department of Clinical Pharmacy,Baiyin First People's Hospital,Baiyin 730900,Gansu Province,China;Department of Pharmacy,Jingmen Hospital of Traditional Chinese Medicine(Municipal Petrochemical Hospital),Jingmen 448000,Hubei Province,China)

机构地区：[1]白银市第一人民医院临床药学科,甘肃白银730900 [2]荆门市中医医院(市石化医院)药剂科,湖北荆门448000

出　　处：《中外医药研究》2024年第18期3-5,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:探讨全程化药学服务对晚期肺癌免疫治疗患者的影响。方法:选取2022年3月—2023年3月于白银市第一人民医院行免疫治疗的晚期肺癌患者83例作为研究对象,根据随机数字表法分为常规组(n=41)和观察组(n=42)。常规组实施临床药师常规指导,观察组实施全程化药学服务。比较两组患者用药依从性、临床疗效及不良反应发生情况。结果:干预后,两组Morisky用药依从性量表评分均升高,且观察组高于常规组,差异有统计学意义(P<0.001)。两组客观缓解率及疾病控制率比较,差异无统计学意义(P>0.05)。观察组3~4级不良反应发生率低于常规组,差异有统计学意义(P=0.038);两组1~2级不良反应发生率及总发生率比较,差异无统计学意义(P>0.05)。结论:应用全程化药学服务可提高晚期肺癌免疫治疗患者的用药依从性,降低患者3~4级不良反应发生率。Objective:To explore the effect of whole-process pharmaceutical care on patients with advanced lung cancer immunotherapy.Methods:Eighty-three patients with advanced lung cancer who received immunotherapy in Baiyin First People's Hospital from March 2022 to March 2023 were selected as the study objects,and were divided into routine group(n=41)and observation group(n=42)according to random number table method.The routine group implemented the routine guidance of clinical pharmacists,and the observation group implemented the whole-process pharmaceutical care.The medication compliance,clinical efficacy and adverse reactions were compared between the two groups.Results:After intervention,the score of Morisky medication compliance scale increased in both groups,and the observation group was higher than the routine group,the difference was statistically significant(P<0.001).There was no significant difference in objective remission rate and disease control rate between the two groups(P>0.05).The incidence of grade 3 to 4 adverse reactions in observation group was lower than that in routine group,and the difference was statistically significant(P=0.038).There was no significant difference in the incidence and total incidence of grade 1 to 2 adverse reactions between the two groups(P>0.05).Conclusion:The application of whole-process pharmaceutical care can improve the medication compliance of patients with advanced lung cancer immunotherapy and reduce the incidence of grade 3 to 4 adverse reactions.

关 键 词：全程化药学服务 晚期肺癌 免疫治疗 用药依从性 

分 类 号：R734.2[医药卫生—肿瘤]